Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders.
暂无分享,去创建一个
[1] C. Mengoli,et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.
[2] L. Gavaldá,et al. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. , 2007, Vaccine.
[3] Araceli Hernández,et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. , 2007, Biologicals : journal of the International Association of Biological Standardization.
[4] S. Husain,et al. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. , 2005, World journal of gastroenterology.
[5] J. Hildebrandt,et al. Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[6] T. Jones,et al. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[7] A. Floreani,et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. , 2004, Vaccine.
[8] M. Hilleman. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. , 2003, Vaccine.
[9] S. Lal,et al. Immuneresponse to recombinant hepatitis B vaccination in adults. , 2003, The Journal of communicable diseases.
[10] I. D. de Messias-Reason,et al. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. , 2003, Vaccine.
[11] S. Reif,et al. Decreased immune response to hepatitis B eight years after routine vaccination in Israel , 2003, Acta paediatrica.
[12] F. Otaǧ. False positive HBsAg result in blood donors due to administration of three different recombinant DNA Hepatitis B vaccines. , 2003, Vaccine.
[13] H. van Loveren,et al. Cytokine Polymorphisms Play a Role in Susceptibility to Ultraviolet B-Induced Modulation of Immune Responses after Hepatitis B Vaccination1 , 2003, The Journal of Immunology.
[14] G. Drusano,et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. , 2003, Vaccine.
[15] S. Agarwal,et al. Efficacy of GM-CSF as an Adjuvant to Hepatitis B Vaccination in Patients with Chronic Renal Failure—Results of a Prospective, Randomized Trial , 2003, Renal failure.
[16] H. van Loveren,et al. IL-1beta gene polymorphisms influence hepatitis B vaccination. , 2002, Vaccine.
[17] M. Yaron,et al. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.
[18] R. Idilman,et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C , 2002, American Journal of Gastroenterology.
[19] L. Doğancı,et al. Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. , 2001, Central European journal of public health.
[20] J. Holley,et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. , 2000, Clinical nephrology.
[21] C. Tinelli,et al. Early immunisation with hepatitis B vaccine: a five-year study. , 2000, Vaccine.
[22] B. Bastani,et al. Granulocyte-Macrophage Colony-Stimulating Factor as an Adjuvant to Hepatitis B Vaccination in Maintenance Hemodialysis Patients , 2000, American Journal of Nephrology.
[23] U. Liebert,et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C , 2000, Hepatology.
[24] J. Treanor,et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. , 1999, The Journal of infectious diseases.
[25] S. Sarin,et al. Granulocyte–macrophage colony‐stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients , 1999, Journal of viral hepatitis.
[26] L. Hwang,et al. Hepatitis B vaccination in high-risk infants: 10-year follow-up. , 1999, The Journal of infectious diseases.
[27] H. Margolis,et al. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. , 1998, American journal of preventive medicine.
[28] P. Goldwater. Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders , 1997 .
[29] M. Guillaume,et al. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. , 1996, Vaccine.
[30] K. Deusch,et al. The effect of granulocyte—macrophage colony‐stimulating factor (GM‐CSF) on hepatitis B vaccination in haemodialysis patients , 1996, Journal of viral hepatitis.
[31] M. Kane. Global programme for control of hepatitis B infection. , 1995, Vaccine.
[32] P. Linsley,et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. , 1994, Journal of immunology.
[33] A. Burgess,et al. Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .
[34] R. Steinman,et al. The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.
[35] S. Meuer,et al. Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. , 1990, Kidney international.
[36] M. Garovoy,et al. Altered monocyte function in uremia. , 1990, Clinical immunology and immunopathology.
[37] E. Engleman,et al. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. , 1990, The Journal of clinical investigation.
[38] S. Meuer,et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.
[39] J. Lifter,et al. T cell subsets and cellular immunity in end-stage renal disease. , 1983, The American journal of medicine.
[40] W. Wilson,et al. IMMUNOLOGIC STUDIES IN HUMAN ORGAN TRANSPLANTATION I. OBSERVATION AND CHARACTERIZATION OF SUPPRESSED CUTANEOUS REACTIVITY IN UREMIA , 1964 .
[41] M. Prinzmetal,et al. Studies on coronary circulation; quantitative changes in a serum mucoprotein following the occurrence of myocardial infarction. , 1949, The American journal of medicine.